Assessment of validity and reliability of drug hypersensitivity quality of life questionnaire: the Dutch experience
Beyond glucose-lowering, tirzepatide achieved remarkable and sustained weight loss, with mean reductions exceeding 20% in non-diabetic adults with obesity after 72 weeks
According to data from Grand View Research, the GLP-1RA market in the Asia-Pacific region reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, representing a compound annual growth rate (CAGR) of 14% [1] , making it one of the fastest-growing regions globally
Serious Side Effects (Rare) Serious adverse events were reported in 4.8% and 3.5% of participants respectively One case of adjudication-confirmed pancreatitis was reported (in the semaglutide group) No deaths occurred in either treatment group No cases of medullary thyroid cancer or pancreatic cancer were reported When to Contact Your Doctor Seek medical attention if you experience: Severe or persistent abdominal pain (possible sign of pancreatitis) Signs of an allergic reaction (rash, swelling, difficulty breathing) Symptoms of low blood sugar (shakiness, dizziness, confusion) Persistent vomiting or inability to keep fluids down Any new or worsening symptoms Horizontal bar chart comparing common side effects of tirzepatide and semaglutide including nausea constipation diarrhoea and vomiting from SURMOUNT-5 trial data Tips for Getting the Most from Your Treatment The medication works alongside, not instead of, healthy lifestyle habits
Repeated exposure to gastric acid can erode tooth enamel, particularly affecting the lingual (tongue-facing) surfaces of teeth
Er dient echter nog meer onderzoek te worden gedaan willen we concluderen of het echt werkt voor mensen met overgewicht n zomaar veilig gebruikt kan worden
